
    low patient accrual
  
['breast cancer', 'lymphoma', 'pain']
['pregabalin', 'placebo']

        Inclusion Criteria:

          -  Age ≥18 years

          -  Diagnosis of a non-myeloid hematologic malignancy scheduled to initiate a cycle of
             chemotherapy that requires prophylactic use of a granulocyte colony-stimulating growth
             factor (based on the provider's discretion), provided the schedule of chemotherapy
             cycles allows the use of pegfilgrastim at a dose of 6 mg SC once per cycle OR
             Diagnosis of breast cancer scheduled to initiate dose-dense doxorubicin and
             cyclophosphamide (AC) chemotherapy or docetaxel and cyclophosphamide (TC) chemotherapy
             that requires prophylactic use of a granulocyte colony-stimulating growth factor,
             provided the schedule of chemotherapy cycles allows the use of pegfilgrastim, at a
             dose of 6 mg SC once per cycle; pegfilgrastim scheduled for 24 hours post
             chemotherapy.

          -  Schedule of chemotherapy and pegfilgrastim initiation can accommodate initiation of
             pregabalin 4 days prior to pegfilgrastim dose.

          -  Baseline pain scores <7 as measured via 10-point numerical scale for pain (see section
             11.1); pain score and use of any non-opioid pain medication must be self-reported as
             stable (same dose and frequency) over the 7 days prior to screening; for opioids,
             patient must self-report the same dose and frequency over the 28 days prior to
             screening. Patients who are receiving peri-procedural short-acting analgesics will
             still be included as long as they are no longer receiving analgesics by D1 of
             chemotherapy.

        Exclusion Criteria:

          -  A history of (within one month) or current pregabalin use.

          -  Baseline pain scores ≥7 as measured via 10-point numerical scale for pain (see section
             11.1).

          -  Unwilling to discontinue use of antihistamines from 7 days prior to D1 of study
             medication.

          -  Creatinine clearance (CrCl) ≤60 ml/min (as measured via Cockcroft-Gault) based on
             serum creatinine measured as part of standard of care prior to administration of
             chemotherapy

          -  Women of childbearing potential must have a negative serum pregnancy test prior to
             initiating therapy (note, this test should be standard of care prior to administration
             of chemotherapy).

          -  Patient is unable or unwilling to abide by the study protocol or cooperate fully with
             the investigator.

          -  Eligible and agrees to enroll into therapeutic trial ongoing at the Lineberger
             Comprehensive Cancer Center (LCCC) (i.e., the treatment trial will take precedence
             over LCCC1314).

          -  Currently receiving therapeutic doses of anticoagulants (ie, prophylactic use of
             anticoagulants is allowed) due to possibility of dizziness and falls while on
             pregabalin.

          -  Currently receiving aromatase inhibitors or agents targeted against Ph+ leukemias
             (i.e., imatinib, dasatinib, nilotinib, and ponatinib) or scheduled to start these
             drugs during cycle 1 of scheduled chemotherapy.

          -  Presence of bone metastases.

          -  History of angioedema.

          -  History of a seizure disorder.
      